

## Steve Abrams

Partner

Philadelphia

### Biography

As Global Co-Head of our Life Sciences & Health Care industry sector, Steve Abrams works with clients in many areas of the life sciences ecosystem, such as oncology therapies, pain products, dermatology therapies, vaccines, diagnostics, medical devices and drug/device combinations, orphan drugs, and gene therapies. He also counsels a variety of companies that provide services to the life sciences industry.

Steve has successfully negotiated and completed a range of life sciences transactions, with a particular focus on capital market offerings (IPOs, follow-on offerings, ATMs, RDOs, PIPES, and private placements), collaboration/licensing transactions, and M&A transactions. Additionally, he regularly advises public and privately held clients, including boards of directors, on securities, governance, transactional, and a range of other complex issues.

Steve is a member of the board of directors of inTEST Corporation (NASDAQ: INTT), and a member of its Audit and Compensation Committees. He is Chair of its Nominating Committee as well. Steve has lectured in front of various groups and published articles on securities, governance, and M&A issues.

### Representative experience



### Phone

+1 267 675 4671

### Fax

+1 267 675 4601

### Email

[steve.abrams@hoganlovells.com](mailto:steve.abrams@hoganlovells.com)

---

### Practices

Mergers and Acquisitions

Corporate Governance

Capital Markets

Securities and Public Company  
Advisory

Commercial

---

### Industries

Life Sciences and Health Care

Private Capital

---

### Areas of focus

Shareholder Activism

Represented a commercial-stage pharmaceutical company in US\$46m follow-on offering led by Cowen and Cantor Fitzgerald.

Represented a commercial-stage pharmaceutical company in US\$100m and US\$50m follow-on offerings led by Jefferies, Cowen, and Piper Jaffray.

Represented a commercial-stage pharmaceutical company on its US\$70m follow-on offering and US\$90m at-the-market offering.

Represented a clinical-stage pharmaceutical company on its US\$50m at-the-market offering.

Represented an Australian-based clinical-stage pharmaceutical company on its US\$40m private placement.

Represented a clinical-stage biotechnology company in US\$40m and US\$30m follow-on offerings and its US\$35m at-the-market offering.

Represented a publicly traded biotechnology company in its US\$63m sale.

Represented a publicly traded commercial-stage pharmaceutical company on an acquisition of a privately held specialty pharmaceutical company.

Represented a pre-clinical-stage pharmaceutical company in its US\$48m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.\*

Represented a clinical-stage pharmaceutical company in its US\$80m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.\*

Represented a NASDAQ Global Market developer and supplier of injectable drug delivery systems in a US\$45m underwritten offering of common stock.\*

Represented a clinical-stage biopharmaceutical

Cross-border Mergers and Acquisitions

Hostile Takeovers and Takeover Defense

Public Company Mergers and Acquisitions

Special Committee and Independent Director Representations

Cell, Tissue, and Gene Therapies

---

## Education and admissions

### Education

J.D., University of Pennsylvania Law School, cum laude, 1995

B.A., Rutgers University, summa cum laude, 1990

---

## Bar admissions and qualifications

Pennsylvania

New Jersey

---

company in its US\$40m at-the-market equity program led by Cowen and Company.\*

Represented a publicly traded clinical stage pharmaceutical company in a US\$65.6m underwritten offering of common stock.\*

Represented a provider of integrated clinical documentation solutions for the U.S. health care system in a US\$130m acquisition.\*

Represented a provider of integrated promotional outsource services to life sciences companies in its US\$55m acquisition.\*

Represented a specialty pharmaceutical company in its US\$138m IPO of common stock through a syndicate of underwriters led by Jefferies and Piper Jaffray.

Represented a specialty pharmaceutical company in its acquisition of a commercial-stage specialty pharmaceutical company and related equity and debt financing.

Represented a clinical-stage oncology company in its reverse merger into a NASDAQ-listed public company.

Represented a specialty pharmaceutical company in its co-promotional agreement with a major orthopaedic company.

Represented a commercial-stage specialty pharmaceutical company in its US\$120m follow-on public offering through a syndicate of underwriters led by Jefferies and Piper Jaffray.

Represented Arbutus Biopharma Corporation on an at-the-market equity offering led by Jefferies.

\*Matter handled prior to joining Hogan Lovells.

## Awards and rankings

- Corporate and M&A, Notable Practitioner, *IFLR1000*, 2020

- Pharmaceuticals and life sciences, Notable Practitioner, *IFLR1000*, 2020
- Finance: Capital Markets: Equity Offerings, *Legal 500 US*, 2017-2018, 2020
- Life Sciences Star, *LMG Life Sciences*, 2018-2019

## Latest thinking and events

- Hogan Lovells Publications
  - Principles matter: SEC amends disclosure rules for business, legal proceedings, and risk factors *SEC Update*
- Hogan Lovells Publications
  - More investors to be accredited under amended SEC rules *SEC Update*
- Hogan Lovells Publications
  - Supreme Court upholds limited SEC right to obtain disgorgement in court enforcement proceedings *SEC Update*
- Press Releases
  - Hogan Lovells announces changes to office, practice area, and industry sector leadership roles
- Hogan Lovells Publications
  - SEC amends rules on financial reporting of business acquisitions and dispositions *SEC Update*
- Hogan Lovells Publications
  - Practical insights for boards of directors in the time of COVID-19